Cancer Vaccines as Immunotherapy of Cancer

Authors

Luigi Buonaguro Head of Cancer Immunoregulation Unity, National Cancer Institute "Pascale�, Italy. Luigi Buonaguro, PhD, is Head of Cancer Immunoregulation Unity at National Cancer Institute "Pascale� in Italy. His primary interest is the identification of novel target tumor antigens. In particular, Dr. Buonaguro is coordinating the development of a novel therapeutic cancer vaccine for liver cancer. Sjoerd Van Der Burg Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, The Netherlands. Sjoerd Van Der Burg, PhD, is Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, at Leiden University Medical Center, in The Netherlands. His primary interest is the exploration of key factors in host-tumor interactions that determine successes and failures in the immunotherapy of cancer. Dr. Van Der Burg co-developed the synthetic long peptide vaccine concept, in particular for HPV-induced cancers and currently is developing a vaccine to stimulate the immune response to TAP-deficient tumors.Sjoerd Van Der Burg, PhD, is Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, at Leiden University Medical Center, in The Netherlands. His primary interest is the exploration of key factors in host-tumor interactions that determine successes and failures in the immunotherapy of cancer. Dr. Van Der Burg co-developed the synthetic long peptide vaccine concept, in particular for HPV-induced cancers and currently is developing a vaccine to stimulate the immune response to TAP-deficient tumors.